Inquiry Basket
Loading ......
Measuring 25-OH Vitamin D, also known as 25-hydroxyvitamin D or 25(OH)D, is one of the most common approaches for evaluating vitamin D status. Antibody-based immunoassays are widely used in clinical laboratories because they can be integrated into automated, high-throughput testing workflows and provide relatively rapid results. These assays use antibodies or antibody-based recognition systems to detect 25(OH)D in blood samples and typically report the combined concentration of 25(OH)D2 and 25(OH)D3. Although different platforms use different reagents, labels, and reaction configurations, they share the same fundamental goal: converting specific molecular recognition of 25(OH)D into a measurable analytical signal.
25(OH)D is the major circulating form used to assess vitamin D status. Compared with the active hormone 1,25-dihydroxyvitamin D, 25(OH)D remains in circulation for a longer period and better reflects the body's overall vitamin D stores. Blood 25(OH)D consists primarily of 25(OH)D2 and 25(OH)D3, which originate from different vitamin D sources. For this reason, a reliable vitamin D assay needs to recognize these metabolites appropriately and provide a measurement that represents total circulating 25(OH)D.
A major analytical challenge is that most circulating 25(OH)D is tightly associated with vitamin D-binding protein (VDBP), with additional binding to albumin. Before antibody recognition can occur efficiently, the metabolite generally needs to be released from these endogenous protein complexes. Many immunoassays therefore incorporate a release reagent or pretreatment solution designed to disrupt the interaction between 25(OH)D and its binding proteins. Some systems use proprietary release chemistry, while others employ alkaline conditions such as sodium hydroxide-based pretreatment. The effectiveness of this step is important because incomplete release can reduce analyte accessibility and potentially influence the measured concentration.
Competitive immunoassay is the most established format for antibody-based 25(OH)D measurement because 25(OH)D is a relatively small molecule and cannot readily support the conventional two-site antibody binding required by a traditional sandwich assay. In a competitive system, 25(OH)D in the patient sample competes with a labeled vitamin D-related tracer for a limited amount of antibody-binding capacity. When the sample contains more 25(OH)D, more antibody-binding sites are occupied by the sample analyte, leaving fewer sites available for the labeled tracer. As a result, the detected signal generally decreases as the concentration of 25(OH)D increases, and the instrument uses a calibration curve to convert this inverse signal relationship into a quantitative concentration.
Chemiluminescent immunoassays have become an important format for automated 25(OH)D testing because they combine immunochemical recognition with highly sensitive light-based detection. Depending on the platform, antibodies may be immobilized on magnetic or paramagnetic particles, while a vitamin D-related tracer carries a chemiluminescent label. After the sample and reagents undergo the required reaction and separation steps, a chemical trigger produces light that is measured by the analyzer as a signal such as relative light units. Because these assays are generally competitive, the measured signal has an inverse relationship with the concentration of 25(OH)D in the sample, although the exact reaction sequence, particle system, tracer chemistry, and calibration strategy differ among manufacturers.
ELISA provides another widely used antibody-based approach for measuring 25(OH)D and generally applies the same competitive immunochemical principle with a different signal-generation mechanism. After sample pretreatment releases 25(OH)D from binding proteins, the sample participates in a competitive reaction involving an antibody and a labeled vitamin D-related reagent. An enzyme-linked detection system subsequently generates a colored product, and the absorbance is commonly measured using a microplate reader. Because the assay is competitive, higher concentrations of 25(OH)D generally produce lower optical signals. The measured absorbance is compared with calibrators to determine the concentration of 25(OH)D in the sample.
Traditional sandwich immunoassays are difficult to apply to 25(OH)D because the molecule is too small to provide two sufficiently separated binding sites for two conventional antibodies. However, newer assay designs have explored alternative sandwich-like strategies in which the analytical target is an immune complex rather than the small molecule alone. In such approaches, one antibody can first interact with 25(OH)D to form a detectable complex, followed by recognition of that complex by a second antibody or another binding reagent. This strategy expands the possibilities for immunochemical detection of small molecules while maintaining the general concept of generating a measurable signal through multiple recognition events.
An important characteristic of many clinical 25(OH)D immunoassays is their intended recognition of both 25(OH)D2 and 25(OH)D3 so that the final result represents total 25(OH)D. Ideally, the antibody and assay chemistry provide comparable responses to the two metabolites, although the actual analytical response depends on antibody characteristics and the overall assay design. Differences in recognition between D2 and D3 can affect measurement accuracy, particularly in samples where one metabolite contributes substantially more to the total concentration. Therefore, manufacturers evaluate the analytical specificity and relative response of their assays during method development and validation.
Different antibody-based vitamin D assays can produce somewhat different numerical results for the same sample because immunoassays are not analytically identical systems. Differences in antibody specificity, 25(OH)D release efficiency, calibration materials, tracer design, reaction time, incubation conditions, matrix effects, and signal-generation technology can all influence the final measurement. The ability of an assay to recognize 25(OH)D2 and 25(OH)D3 with similar efficiency can also affect comparability. Consequently, a vitamin D result should always be interpreted in the context of the specific analytical method used, particularly when monitoring changes over time or comparing results generated by different laboratories.
Antibody-based immunoassays and liquid chromatography-tandem mass spectrometry (LC-MS/MS) measure 25(OH)D using fundamentally different analytical strategies. Immunoassays depend on antibody-mediated molecular recognition and are well suited to routine, automated, high-throughput testing, whereas LC-MS/MS separates individual metabolites chromatographically before detecting them according to their mass-to-charge characteristics. One major advantage of LC-MS/MS is its ability to distinguish and quantify 25(OH)D2 and 25(OH)D3 separately, while many immunoassays are designed primarily to provide a total 25(OH)D result. The choice between these approaches therefore depends on the required analytical specificity, laboratory workflow, instrumentation, sample characteristics, and intended application.
An antibody-based 25(OH)D result generally represents an estimate of the total concentration of circulating 25(OH)D, including contributions from 25(OH)D2 and 25(OH)D3 when the assay is designed for comparable recognition of both metabolites. The result is used to evaluate vitamin D status and should not be interpreted as a direct measurement of active vitamin D hormone activity or vitamin D receptor signaling. Interpretation should take into account the laboratory's validated analytical method, applicable reference information, patient characteristics, and clinical context rather than relying on the numerical concentration alone.
Reliable 25(OH)D measurement depends not only on antibody quality but also on calibration, traceability, sample preparation, analytical specificity, quality control, and overall assay design. Standardization is particularly important because differences between historical and contemporary vitamin D methods can make results difficult to compare across laboratories or over time. For routine monitoring, using the same validated assay platform when possible can improve the consistency of longitudinal measurements. In research, clearly documenting the analytical method and assay characteristics is equally important because it allows results from different experiments or studies to be interpreted more appropriately.
Antibody-based immunoassays measure 25-OH Vitamin D by releasing 25(OH)D from its endogenous binding proteins and using antibody-mediated recognition to convert the analyte concentration into a measurable signal. Competitive immunoassays remain the dominant approach because the small size of 25(OH)D makes conventional sandwich formats challenging, while ELISA and chemiluminescent platforms use different detection technologies to implement the underlying immunochemical principle. Most assays are designed to measure total 25(OH)D, including 25(OH)D2 and 25(OH)D3, although differences in antibody specificity, calibration, sample pretreatment, and assay architecture can influence results. Understanding these analytical principles is essential for interpreting vitamin D measurements accurately and selecting an appropriate testing method for clinical or research applications.
A 25-OH Vitamin D immunoassay generally measures the total concentration of circulating 25-hydroxyvitamin D, including 25(OH)D2 and 25(OH)D3. The result is primarily used to assess overall vitamin D status.
Most circulating 25(OH)D is bound to vitamin D-binding protein and albumin in blood. A release reagent or pretreatment step helps dissociate 25(OH)D from these proteins, making the metabolite accessible to antibodies and improving the reliability of the measurement.
25(OH)D is a small molecule and cannot easily accommodate two antibodies binding simultaneously at separate sites, as required by a conventional sandwich assay. Competitive immunoassays overcome this limitation by allowing sample 25(OH)D to compete with a labeled vitamin D-related tracer for antibody-binding sites.
Results can vary between assay platforms because of differences in antibody specificity, recognition of 25(OH)D2 and 25(OH)D3, sample pretreatment, calibration materials, reaction conditions, and detection technologies. Therefore, results from different methods should not always be considered directly interchangeable.
Antibody-based assays use specific molecular recognition to measure 25(OH)D and are well suited to automated, high-throughput testing. LC-MS/MS separates and detects vitamin D metabolites based on their chromatographic and mass-spectrometric properties, allowing 25(OH)D2 and 25(OH)D3 to be quantified separately when the method is appropriately configured.
References
| Target | Cat. No. | Product Name | Host | Application | |
| 25-OH Vitamin D | DMABA-JX119 | Rabbit Anti-25 OH Vitamin D monoclonal antibody, clone S594L4 | Rabbit | ELISA, LFIA, CLIA | Inquiry |
| DMABA-JX120 | Rabbit Anti-25 OH Vitamin D monoclonal antibody, clone S595K5 | Rabbit | ELISA, LFIA, CLIA | Inquiry | |
| DMAB-JXL2399 | Goat Anti-25-OH VD2/VD3 Monoclonal Antibody, clone 5C3 | CHO | ELISA, CLIA, LFIA | Inquiry | |
| DMAB2913 | Mouse Anti-25 OH Vitamin D3 monoclonal antibody, clone L35235N | Mouse | ELISA | Inquiry | |
| DMAB2914 | Mouse Anti-25 OH Vitamin D3 Monoclonal antibody, clone C2531M | Mouse | ELISA | Inquiry | |
| CABT-L1343W | Humanized Anti-Human 25-OH-VD Monoclonal antibody, clone 214I2T | Humanized | LFIA, CLIA | Inquiry | |
| CABT-L1344W | Humanized Anti-Human 25-OH-VD Monoclonal antibody, clone 214I5 | Humanized | PETIA | Inquiry |
| Target | Cat. No. | Product Name | Conjugate | Application | |
| 25-OH Vitamin D | DAG-WT2678 | 25-hydroxyvitamin D control | Unconjugated | Calibration, Control | Inquiry |
| DAG-WT2679 | 25-hydroxyvitamin D2 control | Unconjugated | Calibration, Control | Inquiry | |
| DAG-WT2680 | 25-hydroxyvitamin D3 control | Unconjugated | Calibration, Control | Inquiry | |
| DAG03219 | 25-OH Vitamin D3 [BSA] | BSA | ELISA, LFIA | Inquiry | |
| DAGA-126H | 25-OH Vitamin D [HRP] | HRP | ELISA | Inquiry | |
| DAGA-126K | 25-OH Vitamin D [KLH] | KLH | Immunogen | Inquiry | |
| DAG-WT6032B | 25-OH Vitamin D2 [BSA] | BSA | ELISA, LFIA | Inquiry |
| Target | Cat. No. | Product Name | Species Reactivity | Application | Detection Sample | |
| 25-OH Vitamin D | DEIA4458 | 25-OH Vitamin D ELISA Kit | Human | Quantitative | Serum, Plasma | Inquiry |
| DEIA1733 | 25 (OH) Vitamin D ELISA Kit | Human | Quantitative | plasma, serum | Inquiry | |
| DEIA002J | 25-OH Vitamin D direct (1-point calibration) ELISA Kit | Human | Quantitative | serum | Inquiry | |
| DEIA003J | 25-OH Vitamin D direct day ELISA Kit | Human | Quantitative | serum, fresh plasma | Inquiry | |
| DEIA004J | 25-OH Vitamin D direct ELISA Kit | Human | Quantitative | serum, fresh plasma | Inquiry | |
| DEIA005J | 25-OH Vitamin D Xpress ELISA Kit | Human | Quantitative | serum, fresh EDTA plasma | Inquiry | |
| DEIA006J | 25-OH Vitamin D ELISA Kit | Human | Quantitative | serum, plasma | Inquiry | |
| DEIA2219 | 25-OH Vitamin D (total) ELISA Kit | Human | Quantitative | Serum | Inquiry | |
| DEIA-BJ574-1 | Human 25 (OH) D3 ELISA kit | Human | Quantitative | Serum, plasma and other biological fluids. | Inquiry | |
| DEIA-BJ2145 | Rat 25 Hydroxy Vitamin D3 ELISA Kit | Rat | Quantitative | Serum, plasma, cell culture supernatants, body fluid and tissue homogenate | Inquiry | |
| DEIA-NS2651 | 25OH-D (Total 25-OH Vitamin D) ELISA Kit | Universal | Quantitative | Serum, plasma, cellculture supernatant and other biological samples. | Inquiry | |
| DEIA-BJ648 | Human 25 Hydroxy Vitamin D ELISA kit | Human | Quantitative | biological fluids. | Inquiry |
Loading ......
